Tablet Levair 2mg

Presentation :
Levair 1 : Each tablet contains Levosalbutamol Sulphate equivalent to Levosalbutamol INN
1 mg.
Levair 2 : Each tablet contains Levosalbutamol Sulphate equivalent to Levosalbutamol INN
2 mg.
Levair Syrup : Each 5 ml syrup contains Levosalbutamol Sulphate equivalent to
Levosalbutamol INN 1 mg.
Description :
Levosalbutamol is the R-isomer of racemic Salbutamol having beta 2 agonist activity.
Levosalbutamol is an effective bronchodilator whose primary mechanism of action is not
inhibited by S-Salbutamol. Thus, when compared with racemic Salbutamol, clinically
comparable bronchodilation can be achieved with doses that substantially lessen
beta-mediated side effects.
Indications :
Levosalbutamol is indicated for the relief of bronchospasm in conditions such as asthma
and COPD in adults, adolescents, and children 6 years of age and older.
Dosage and Administration :
Levair Tablet :
Adult and adolescents above 12 years : 1-2 mg three times daily.
Children (6-11 years) : 1 mg three times daily.
Levair Syrup :
Adults and adolescents above 12 years : 5-10 ml three times daily.
Children (6-11 years) : 5 ml three times daily.
Missed Dose :
The missed dose should be taken as soon as the patient remembers. However, if it is
almost time for the next regularly scheduled dose, should be skipped the missed dose and
should be taken the next one as directed. It should not be taken a double dose at a time of
this medication.
Contraindications :
Levosalbutamol is contraindicated in patients with a history of hypersensitivity to this
compound or any of the components of this formulation.
Precautions :
Potentially serious hypokalemia may result from beta 2 agonist therapy. Particular caution is
advised in acute severe asthma as this effect may be potentiated by hypoxia and by
concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium
levels should be monitored in such situations.
Levosalbutamol, like all other beta adrenergic agonists, can produce a clinically significant
cardiovascular effect in some patients, as measured by pulse rate, blood pressure and/or
symptoms. Although such effects are uncommon after administration of Levosalbutamol at
recommended doses.
Drug Interactions :
Other short-acting sympathomimetic bronchodilatrors or epinephrine should be used with
caution with Levosalbutamol. Combination requiring precaution with beta-blockers,
diuretics, digoxin and specially with monoamine oxidase inhibitors or tricyclic
antidepressants.
Use in Pregnancy and Lactation :
Use of oral Levosalbutamol in pregnant women should be considered only if the expected
benefit to the mother is greater than any possible risk to the fetus or the infant. It is not
known whether Levosalbutamol is excreted in human milk. Caution should be exercised
when oral Levosalbutamol is administered to a nursing woman.
Side Effects :
Potentially serious hypokalaemia may result from beta 2 agonist therapy. This effect may be
potentiated by hypoxia. Particular caution is advised in severe asthma, with monitoring of
serum potassium levels. Other side effects such as palpitation, fine tremors of the skeletal
muscle (Particularly the hand) and muscle cramps may occur. The other likely side effects
are gastrointestinal disturbances such as nausea, vomiting, burning substernal of epigastric
pain and diarrhoea. In some cases nervousness, headache, dizziness, fatigue and
sleeplessness may occur.
Overdosage :
The expected symptoms with overdosage are those of excessive beta-adrenergic
stimulation and/or occurrence of exaggeration of any of the symptoms listed under side
effects e.g. tachycardia, nervousness, headache, tremor, nausea, dizziness, fatigue and
sleeplessness. Hypokalaemia also may occur. Treatment consists of discontinuation of oral
Levosalbutamol together with appropriate symptomatic therapy. In the event of serious
poisoning, the stomach should be emptied and, if necessary, a beta-blocker administered
with caution in patients with a history of bronchospasm.
Storage Condition :
Store in a cool & dry place, protected from light. Keep out of reach of children.
Commercial Pack :
Levair 1 : Each box contains 10 blister packs of 10 tablets.
Levair 2 : Each box contains 5 blister packs of 10 tablets.
Levair Syrup : Each PET bottle contains 100 ml syrup with a measuring cup.